GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Investing.com -- GSK (NYSE: GSK) (LON: GSK) said on Monday that the U.S. Food and Drug Administration has accepted its ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

Kaivan Khavandi, Senior Vice President and Global Head of Respiratory, Immunology and Inflammation R&D at GSK, stated, “The close of our acquisition for efimosfermin alfa represents a significant ...

London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and ...

As you might know, GSK plc (LON:GSK) recently reported its interim numbers. GSK reported UK£16b in revenue, roughly in line ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...